Rezolute, Inc. Quarterly report pursuant to Section 13 or 15(d)

SUBSEQUENT EVENTS (Details)

SUBSEQUENT EVENTS (Details) - USD ($)			1 Months Ended	3 Months Ended			9 Months Ended
SUBSEQUENT EVENTS (Details) - USD ($)	Apr. 01, 2024	Mar. 08, 2024	May 13, 2024	Jun. 30, 2024	Mar. 31, 2024	Mar. 31, 2023	Mar. 31, 2024	Mar. 31, 2023
Subsequent Event [Line Items]
Loss from change in fair value of derivative liabilities					$ (1,959,000)	$ (14,000)	$ (1,991,000)	$ (40,000)
Warrant derivative liability					7,647,000		7,647,000
Securities exchange agreement
Subsequent Event [Line Items]
Outstanding shares percentage		7.00%
Securities exchange agreement \| Exchange Pre-Funded Warrants
Subsequent Event [Line Items]
Warrants exercisable, ownership blocker percentage		9.99%
Outstanding shares percentage		7.00%
Change in fair value of derivative liability					1,950,000		1,950,000
Warrant derivative liability		$ 5,700,000			$ 7,600,000		7,600,000
Scenario, Upon First Dosing Of The First Patient \| XOMA (US) LLC \| Phase 3 Clinical Trial RZ 358 \| Xoma License Agreement
Subsequent Event [Line Items]
Milestone closing payment							$ 5,000,000.0
Maximum \| Securities exchange agreement \| Exchange Pre-Funded Warrants
Subsequent Event [Line Items]
Warrants exercisable, ownership blocker percentage		19.99%
Subsequent Event \| Securities exchange agreement \| Exchange Pre-Funded Warrants
Subsequent Event [Line Items]
Change in fair value of derivative liability			$ 900,000
Loss from change in fair value of derivative liabilities				$ (900,000)
Warrant derivative liability			$ 8,600,000
Subsequent Event \| Scenario, Upon First Dosing Of The First Patient \| XOMA (US) LLC \| Phase 3 Clinical Trial RZ 358 \| Xoma License Agreement
Subsequent Event [Line Items]
Milestone closing payment	$ 5,000,000.0